PMGC subsidiary Northstrive grants exclusive animal-health license to Modulant Biosciences

PMGC Holdings Inc.

License covers non-human animal health (feed additives) worldwide excluding South Korea.
Modulant pays revenue share; percentages and threshold amount are redacted.
License is subject to a head license; term ends on expiration of last valid patent claim.
Modulant agrees to non-compete for myostatin/Activin-A directed products during term.
Agreement incorporates binding term sheet dated May 12, 2025, previously disclosed.

item 1.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

PMGC Holdings Inc. entered into License Agreement with Modulant Biosciences LLC (effective 2026-02-04).

Action: entry
Agreement: license
Counterparty: Modulant Biosciences LLC
Effective: 2026-02-04

Exact text from the filing

On February 4, 2026, Northstrive Biosciences Inc., a Delaware corporation (“Northstrive Biosciences”) and wholly owned subsidiary of PMGC Holdings Inc. (“Company”), entered into the License Agreement (“License Agreement”) with Modulant Biosciences LLC (“Modulant,” and, together with Northstrive Biosciences, the “Parties”), an Indiana limited liability company.

View on SEC.gov

308 material agreements filed in the last 30 days. Browse all material agreements →

PMGC Holdings Inc. filing history →

Source: SEC EDGAR

accession 0001213900-26-014285

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.